Pfizer exits South San Francisco

Pfizer has fully walked away from its South San Francisco office at 181 Oyster Point Boulevard. The exit clears out about 164,000 square feet of lab and office space and ends the company’s remaining Bay Area footprint, a surprisingly short chapter for a tenant that only arrived in force after buying Global Blood Therapeutics in 2022 for $5.4 billion. That deal was supposed to deepen Pfizer’s position in rare blood disorders. Instead, four years later, the space is empty. That speed matters because South San Francisco is not just another office market. It is the old center of Bay Area biotech, the place where big drug companies planted flags to stay close to talent, venture money, and each other. When a company like Pfizer leaves entirely, it is not a routine lease move. It is a signal that the local market is still digesting a much larger hangover from the life-science boom. The property itself shows why the exit lands hard. 181 Oyster Point was marketed as a modern lab-and-office campus in the middle of the biotech corridor, with five floors and a mix of research and support space. Pfizer had already tried to shrink its footprint there, putting roughly 91,000 square feet on the sublease market before deciding to shut the site altogether. That usually means the first plan failed. There was not enough demand for a partial fix. And demand has been the real story in South San Francisco for a while. Life-science vacancy in the area reached roughly 35 percent in late 2025, according to CBRE data cited in recent coverage. That is an astonishing number for a submarket that spent years defined by scarcity. The problem is not that biotech disappeared. The problem is that too much space arrived just as hiring slowed, venture funding tightened, and larger tenants stopped taking extra room simply because they could. That is why Pfizer’s departure changes more than one building. Big blocks of lab space are hard to backfill. Most tenants in the market now want smaller suites, often in the 5,000- to 20,000-square-foot range, not a single 100,000-square-foot-plus commitment. A full building vacancy can sit for a long time unless an owner breaks it up, spends heavily on upgrades, or accepts a very different kind of tenant. That creates a second-order effect along Oyster Point. Owners who once pitched pure biotech space now have to think about hybrid lab-office layouts, cheaper rents, and repositionings that would have sounded unnecessary a few years ago. In a tighter market, a departure like this would be absorbed quietly. In this one, it adds pressure to every nearby landlord trying to explain why their building is different from the empty one down the street. Pfizer’s explanation appears simple: the site was underused, and staff tied to it will move to remote roles rather than another Bay Area office. The company is not leaving California altogether. It has consolidated more activity in San Diego, where it recently centered oncology research in a new Torrey Heights campus. That makes the South San Francisco closure look less like a one-off real estate decision and more like a map being redrawn inside the company. The result is concrete. A building that was meant to anchor Pfizer’s post-GBT future in the Bay Area is now being marketed floor by floor, with available spaces including a 33,771-square-foot second floor, a 36,884-square-foot third floor, a 36,838-square-foot fourth floor, and a 36,151-square-foot fifth floor.